Underwood Martin, Ashby Deborah, Cross Pamela, Hennessy Enid, Letley Louise, Martin Jeannett, Mt-Isa Shahrul, Parsons Suzanne, Vickers Madge, Whyte Ken
Centre for Health Sciences, Barts and The London, Queen Mary, University of London, London E1 2AT.
BMJ. 2008 Jan 19;336(7636):138-42. doi: 10.1136/bmj.39399.656331.25. Epub 2007 Dec 4.
To determine whether older patients with chronic knee pain should be advised to use topical or oral non-steroidal anti-inflammatory drugs (NSAIDs).
Randomised controlled trial and patient preference study.
26 general practices.
People aged > or =50 with knee pain: 282 in randomised trial and 303 in preference study.
Advice to use topical or oral ibuprofen. Primary outcome measures WOMAC (Western Ontario and McMaster Universities) osteoarthritis index, major and minor adverse effects.
Changes in global WOMAC scores at 12 months were equivalent. In the randomised trial the difference (topical minus oral) was two points (95% confidence interval -2 to 6); in the preference study, it was one point (-4 to 6). There were no differences in major adverse effects in the trial or study. The only significant differences in secondary outcomes were in the randomised trial. The oral group had more respiratory adverse effects (17% v 7%,95% confidence interval for difference -17% to -2%), the change in serum creatinine was 3.7 mmol/l less favourable (0.9 micromol/l to 6.5 micromol/l); and more participants changed treatments because of adverse effects (16% v 1%, -16% to -5%). In the topical group more participants had chronic pain grade III or IV at three months, and more participants changed treatment because of ineffectiveness.
Advice to use oral or topical preparations has an equivalent effect on knee pain over one year, and there are more minor side effects with oral NSAIDs. Topical NSAIDs may be a useful alternative to oral NSAIDs.
ISRCTN 79353052.
确定是否应建议患有慢性膝关节疼痛的老年患者使用外用或口服非甾体抗炎药(NSAIDs)。
随机对照试验和患者偏好研究。
26家全科诊所。
年龄≥50岁的膝关节疼痛患者:随机试验中有282人,偏好研究中有303人。
建议使用外用或口服布洛芬。主要结局指标为WOMAC(西安大略和麦克马斯特大学)骨关节炎指数、主要和次要不良反应。
12个月时总体WOMAC评分变化相当。在随机试验中,差异(外用减去口服)为2分(95%置信区间-2至6);在偏好研究中,为1分(-4至6)。试验或研究中主要不良反应无差异。次要结局的唯一显著差异出现在随机试验中。口服组有更多的呼吸道不良反应(17%对7%,差异的95%置信区间-17%至-2%),血清肌酐变化不利3.7 mmol/l(0.9 μmol/l至6.5 μmol/l);更多参与者因不良反应而更换治疗(16%对1%,-16%至-5%)。在外用组中,更多参与者在3个月时患有III级或IV级慢性疼痛,更多参与者因无效而更换治疗。
建议使用口服或外用制剂对膝关节疼痛在一年中的效果相当,口服NSAIDs的轻微副作用更多。外用NSAIDs可能是口服NSAIDs的有用替代品。
ISRCTN 79353052。